JP2013520467A5 - - Google Patents

Download PDF

Info

Publication number
JP2013520467A5
JP2013520467A5 JP2012554336A JP2012554336A JP2013520467A5 JP 2013520467 A5 JP2013520467 A5 JP 2013520467A5 JP 2012554336 A JP2012554336 A JP 2012554336A JP 2012554336 A JP2012554336 A JP 2012554336A JP 2013520467 A5 JP2013520467 A5 JP 2013520467A5
Authority
JP
Japan
Prior art keywords
formulation
methacrylic acid
methyl methacrylate
copolymer
ethyl acrylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012554336A
Other languages
English (en)
Japanese (ja)
Other versions
JP5645975B2 (ja
JP2013520467A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/052682 external-priority patent/WO2011104275A1/en
Publication of JP2013520467A publication Critical patent/JP2013520467A/ja
Publication of JP2013520467A5 publication Critical patent/JP2013520467A5/ja
Application granted granted Critical
Publication of JP5645975B2 publication Critical patent/JP5645975B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012554336A 2010-02-23 2011-02-23 消化管における吸着剤の経口デリバリー用の製剤 Expired - Fee Related JP5645975B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305179.3 2010-02-23
EP10305179 2010-02-23
PCT/EP2011/052682 WO2011104275A1 (en) 2010-02-23 2011-02-23 Formulations for oral delivery of adsorbents in the gut

Publications (3)

Publication Number Publication Date
JP2013520467A JP2013520467A (ja) 2013-06-06
JP2013520467A5 true JP2013520467A5 (https=) 2014-05-15
JP5645975B2 JP5645975B2 (ja) 2014-12-24

Family

ID=42357439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012554336A Expired - Fee Related JP5645975B2 (ja) 2010-02-23 2011-02-23 消化管における吸着剤の経口デリバリー用の製剤

Country Status (22)

Country Link
US (4) US9968562B2 (https=)
EP (1) EP2538930B1 (https=)
JP (1) JP5645975B2 (https=)
KR (1) KR101820374B1 (https=)
CN (1) CN102869351B (https=)
AU (1) AU2011219788B2 (https=)
BR (1) BR112012021275B1 (https=)
CA (1) CA2790811C (https=)
CY (1) CY1117869T1 (https=)
ES (1) ES2586135T3 (https=)
HR (1) HRP20160834T1 (https=)
HU (1) HUE029299T2 (https=)
IL (1) IL221542A (https=)
LT (1) LT2538930T (https=)
MX (1) MX340822B (https=)
PL (1) PL2538930T3 (https=)
PT (1) PT2538930T (https=)
RS (1) RS54991B1 (https=)
RU (2) RU2012140421A (https=)
SI (1) SI2538930T1 (https=)
WO (1) WO2011104275A1 (https=)
ZA (1) ZA201207068B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340822B (es) * 2010-02-23 2016-07-26 Da Volterra * Formulaciones para suministro oral de adsorbentes en el intestino.
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
CN102432737B (zh) * 2011-09-07 2015-02-25 张绍国 一种缓释肠溶丙烯酸树脂乳胶液及其制法
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
EP2897594B1 (en) 2012-09-21 2020-04-08 Ferring B.V. Pharmaceutical composition
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2014154677A1 (en) * 2013-03-25 2014-10-02 Ferring Bv Composition for the treatment of disease
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
CN108135927A (zh) * 2015-10-06 2018-06-08 达·沃尔泰拉公司 梭菌属细菌的致病性或毒力的抑制或降低
KR20180070591A (ko) * 2015-10-26 2018-06-26 다이이찌 산쿄 가부시키가이샤 다공질 재료의 대장 또는 소장 하부에 대한 딜리버리 제제
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) * 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
RU2750937C2 (ru) * 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
KR101884520B1 (ko) * 2016-07-29 2018-08-02 한국식품연구원 벤토나이트를 유효성분으로 포함하는 염증성 장 질환의 예방 또는 치료용 약학적 조성물
KR102106477B1 (ko) * 2017-01-12 2020-05-06 차장옥 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
BR112020024479A2 (pt) 2018-06-20 2021-03-02 Albireo Ab hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
JP2021533150A (ja) 2018-08-05 2021-12-02 ダ・ヴォルテッラ 移植片対宿主病の治療のための組成物
AU2019317986A1 (en) * 2018-08-05 2021-02-11 Da Volterra Method for improving anticancer agent efficacy
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
CN114599665A (zh) * 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
EP4125847A4 (en) 2020-04-03 2024-06-19 Lpoxy Therapeutics, Inc. ENTERAL AEROBIZATION THERAPY
RU2747401C1 (ru) * 2020-06-22 2021-05-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный университет" Способ получения фармацевтических лекарственных форм на основе сополимеров метилметакрилата
WO2022084550A1 (en) 2020-10-23 2022-04-28 Da Volterra Compositions for use in the treatment or prevention of dysbiosis
WO2022090433A1 (en) 2020-10-30 2022-05-05 Da Volterra Method for the manufacture of an adsorbent formulation
WO2022101267A2 (en) 2020-11-12 2022-05-19 Da Volterra Compositions for delivery of an adsorbent
WO2022101269A1 (en) 2020-11-13 2022-05-19 Da Volterra Formulations and dosage regimen for oral delivery of adsorbents in the gut
WO2023056256A1 (en) 2021-09-29 2023-04-06 Lpoxy Therapeutics, Inc. Enteric aerobization therapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917821A (en) 1973-10-23 1975-11-04 Milton Manes Palatable activated carbon
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5542210A (en) * 1978-09-12 1980-03-25 Koichi Ogawa Special activated carbon
JPS62168540A (ja) * 1986-01-21 1987-07-24 Freunt Ind Co Ltd 被覆方法
JP2798248B2 (ja) * 1986-08-28 1998-09-17 コーテックス リミテッド 生物学的活性物質の動物の腸管部位へのデリバリーに有効なマイクロ顆粒状製剤
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
JPH03120227A (ja) 1989-10-02 1991-05-22 Shigeo Ochi 飲食物消化分解産物吸収抑制剤
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP3338119B2 (ja) * 1993-04-14 2002-10-28 呉羽化学工業株式会社 抗糖尿病剤
US5827497A (en) 1996-08-14 1998-10-27 Mayo Foundation For Medical Education And Research Charcoal-radionuclide agents for measurement of gastrointestinal transit
FR2780052B1 (fr) 1998-06-23 2000-07-21 Ceca Sa Agglomerats a base de charbon actif leur procede de preparation et leur utilisation comme agents d'adsorption
US20040232068A1 (en) 2000-04-21 2004-11-25 Johnston Arthur W. Formation of composite materials with expandable matter
US20020098553A1 (en) * 2001-01-19 2002-07-25 Pierre-Etienne Bost Process for producing carrageenan with reduced amount of insoluble material
CA2344910C (en) * 2001-04-23 2009-07-07 Kureha Chemical Industry Co., Ltd. Method for treating renal disease, and pharmaceutical composition for treating renal disease
EP1306128A1 (en) * 2001-10-29 2003-05-02 Tenaxis Gmbh Sorptive composite materials
JP4486300B2 (ja) 2002-07-25 2010-06-23 ユニ・チャーム株式会社 吸収性物品のトップシート
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
JP3585043B2 (ja) * 2003-01-22 2004-11-04 メルク・ホエイ株式会社 医薬用吸着剤及びその製法
JPWO2004096243A1 (ja) * 2003-04-25 2006-07-13 亘起物産有限会社 便秘予防および改善剤
GB2405343A (en) 2003-08-29 2005-03-02 Johnson & Johnson Medical Ltd Charcoal Wound Dressings
JP4409245B2 (ja) * 2003-10-20 2010-02-03 株式会社荏原製作所 耐食性及び耐摩耗性を有する被覆用合金を用いた装置
KR101135260B1 (ko) 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
TWI370012B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
CA2569684C (en) 2004-06-07 2014-10-07 Kureha Corporation Dry composition for oral ingestion and gel composition prepared just before use for oral ingestion
WO2006044805A2 (en) * 2004-10-15 2006-04-27 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
AU2006249100B2 (en) * 2005-05-18 2012-01-19 Assistance Publique - Hospitaux De Paris Colonic delivery of adsorbents
US20070243268A1 (en) * 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating intestinal disorders and methods of use thereof
US8557274B2 (en) * 2005-12-06 2013-10-15 Purdue Research Foundation Slowly digesting starch and fermentable fiber
US7749497B2 (en) 2005-12-06 2010-07-06 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome
DE102005062160A1 (de) * 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080089943A1 (en) * 2006-08-17 2008-04-17 Xavier Frapaise Use of adsorbent carbon microspheres to treat gastroesophogeal reflux disease
DE202006016898U1 (de) * 2006-10-12 2007-11-22 BLüCHER GMBH Hochleistungsadsorbentien auf der Basis von Aktivkohle mit hoher Mikroporosität
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
WO2008073517A1 (en) * 2006-12-07 2008-06-19 Ehrenpreis Eli D Treatment for intestinal gas, bloating, microscopic colitis and traveler's diarrhea using colloidal bismuth subcitrate
JPWO2008084676A1 (ja) * 2006-12-26 2010-04-30 株式会社 メドレックス 多孔性乾燥マトリックスの医薬組成物
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
US20090148538A1 (en) * 2007-10-12 2009-06-11 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres to treat pouchitis
DE102008014109A1 (de) 2008-03-13 2009-09-17 Bayer Animal Health Gmbh Suspensionsformulierung für Kohlenstoff-Adsorbentien
KR20100001892A (ko) 2008-06-27 2010-01-06 주식회사 에코비젼 핵입자를 함유하는 질산화 미생물의 그래뉼 및 질산화미생물의 그래뉼화 촉진방법
FR2950252B1 (fr) 2009-09-23 2012-01-20 Centre Nat Rech Scient Forme galenique capable d'adsorber de maniere specifique les molecules indesirables
MX340822B (es) * 2010-02-23 2016-07-26 Da Volterra * Formulaciones para suministro oral de adsorbentes en el intestino.

Similar Documents

Publication Publication Date Title
JP2013520467A5 (https=)
RU2016147198A (ru) Лекарственные формы для пероральной доставки адсорбентов в кишечник
HRP20230305T1 (hr) Pripravci za ileo-jejunalnu dostavu lijeka
US20080031867A1 (en) Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20130059010A1 (en) Alcohol-resistant oral pharmaceutical form
JP2018500353A5 (https=)
TW201343202A (zh) 緩釋藥物配方
JP2014528431A5 (https=)
JPH05506217A (ja) 制御放出薬剤処方
EP3154523A1 (en) Formulation for oral administration containing mesalazine
JP2014533656A5 (https=)
JP6554468B2 (ja) ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するため
US20120093939A1 (en) Oral formulations
US20080226738A1 (en) Sustained-Released Pellet Formulation of Alpha1-Receptor Antagonist and Process For the Preparation Thereof
CN101721385B (zh) 一种美沙拉嗪口服控释药物组合物
JP2007530492A5 (https=)
CN103989638B (zh) 一种美沙拉秦缓释颗粒剂及其制备方法
JP2013505284A (ja) 消化管に存在する望ましくない分子を特異的に吸着し得る医学製剤
BR112021010913A2 (pt) Formulação para entrega de fármacos colônicos
MX2014008975A (es) Composicion de nitazoxanida mejorada y proceso para prepararla.
CN101683323A (zh) 含有万古霉素的结肠靶向微丸及其制备方法
HK1180233B (en) Formulations for oral delivery of adsorbents in the gut